Ulrike Ziegner, MD
Pediatric Medicine · Redondo Beach, CANPI 1407867203
Payments from drug & device makers
Across 818 payments — averaging $278.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$80K
- AstraZeneca$78K
- Regeneron$40K
- Teva Pharmaceuticals USA, Inc.$10K
- Shire North American Group Inc$6K
- Sanofi$3K
- plus $10K from 32 others
What the payments were for
- Consulting fees$5,50519%
- Speaking & faculty fees$6,51822%
- Travel & lodging$9233%
- Food & beverage$15,90655%
- Education$1340%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 94 | $80,029 |
| AstraZeneca | 113 | $78,028 |
| Regeneron | 159 | $40,271 |
| Teva Pharmaceuticals USA, Inc. | 24 | $10,480 |
| Shire North American Group Inc | 23 | $5,711 |
| Sanofi | 68 | $2,963 |
| Pfizer | 66 | $1,306 |
| Octapharma USA, Inc. | 13 | $1,272 |
| Amgen | 10 | $1,252 |
| Regeneron Healthcare Solutions, Inc. | 48 | $1,131 |
| CSL Behring | 31 | $1,035 |
| Grifols USA, LLC | 28 | $742 |
| Novartis | 26 | $594 |
| Genentech USA, Inc. | 27 | $572 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $425 |
| Boehringer Ingelheim | 16 | $348 |
| Incyte Corporation | 7 | $284 |
| ARS Pharmaceuticals Operations, Inc. | 5 | $238 |
| AbbVie | 10 | $189 |
| Optinose US, Inc. | 8 | $171 |
| Amarin Pharma, Inc. | 1 | $125 |
| Sanofi-aventis U.S. LLC | 1 | $92 |
| Covidien LP | 1 | $92 |
| LEO Pharma Inc. | 3 | $90 |
| Blueprint Medicines Corporation | 3 | $63 |
| Galderma Laboratories, L.p. | 3 | $55 |
| Alk-abello, Inc | 2 | $45 |
| Kaleo, Inc. | 2 | $43 |
| Lilly USA, LLC | 1 | $31 |
| Jazz Pharmaceuticals Inc. | 1 | $31 |
| Ionis Pharmaceuticals, Inc. | 1 | $26 |
| Merck | 1 | $26 |
| Genentech, Inc. | 1 | $25 |
| Sobi, Inc | 1 | $24 |
| Cycle Pharmaceuticals Inc | 1 | $24 |
| Biocryst Pharmaceuticals, Inc. | 1 | $23 |
| Bio Products Laboratory USA, Inc. | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$227,893 in reported general payments places this provider in the 95th percentile of 52 pediatric medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 36 | $135,317 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 96 | $73,196 |
| KineretAnakinra | 13 | $70,623 |
| Dupixent PenDupilumab | 12 | $52,997 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $14,017 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $9,619 |
| Epinephrine | 31 | $4,151 |
| Montelukast Sodium | 298 | $2,544 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 19 | $364 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 17 | $169 |
| Levothyroxine Sodium | 12 | $63 |
| Prednisone | 19 | $51 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $80,029 | $73,19696 claims |
| AstraZenecaBreztri Aerosphere | $78,028 | $14,01715 claims |
| Boehringer IngelheimStiolto Respimat | $348 | $9,61915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 52 pediatric medicine providers in California.
Other pediatric medicine in Redondo Beach
- Edgar FloresFullerton$13K
- Rasiq AhmedPasadena$969
- Trach DangSan Jose$451
- Nirmita DoshiOakland$0
- Joyce ArpilledaSan Diego$0
- Anna EkstromFremont$0
- Patricia TanseyElk Grove$0
- Margaret KhouryBaldwin Park$0
- Charles PohlWest Hollywood$0
- Allan MarksSan Francisco$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.